SeongJun Han
A5034777818- Cancer Immunotherapy and Biomarkers
- IL-33, ST2, and ILC Pathways
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- Colorectal Cancer Treatments and Studies
- Immune cells in cancer
- Eosinophilic Esophagitis
- Traditional Chinese Medicine Studies
- Cytomegalovirus and herpesvirus research
- Synthesis and Biological Evaluation
- Reproductive System and Pregnancy
- Colorectal Cancer Surgical Treatments
- Pharmacogenetics and Drug Metabolism
- Nutrition, Health and Food Behavior
- Medical Research and Treatments
- Neurological diseases and metabolism
- CRISPR and Genetic Engineering
- Cancer-related gene regulation
- Glycosylation and Glycoproteins Research
- Cancer, Hypoxia, and Metabolism
- Infant Health and Development
- Galectins and Cancer Biology
- RNA regulation and disease
Harvard University
2022-2025
Princess Margaret Cancer Centre
2016-2024
Boston VA Research Institute
2022-2024
University of Toronto
2016-2024
University Health Network
2016-2024
Brigham and Women's Hospital
2022-2024
Massachusetts General Hospital
2024
McMaster University
2014-2016
Health Net
2016
Kyung Hee University
2016
The purpose of this study was to evaluate the prognostic value Immunoscore in patients with stage III colon cancer (CC) and analyze its association effect chemotherapy on time recurrence (TTR).
The manipulation of T cell metabolism to enhance anti-tumor activity is an area active investigation. Here, we report that activating the amino acid starvation response in effector CD8+ cells ex vivo using general control non-depressible 2 (GCN2) agonist halofuginone (halo) enhances oxidative and function. Mechanistically, identified autophagy coupled with CD98-mTOR axis as key downstream mediators phenotype induced by halo treatment. adoptive transfer halo-treated into tumor-bearing mice...
Background: The prognostic value of Immunoscore was evaluated in Stage II/III colon cancer (CC) patients, but it remains unclear I/II, and early-stage subgroups at risk. An international Society for Immunotherapy Cancer (SITC) study the pre-defined consensus tumors from 1885 AJCC/UICC-TNM I/II CC patients Canada/USA (Cohort 1) Europe/Asia 2). METHODS: Digital-pathology is used to quantify densities CD3+ CD8+ T-lymphocyte center tumor (CT) invasive margin (IM). time recurrence (TTR) primary...
CD8+ T cells can be polarized into several different subsets as defined by the cytokines they produce and transcription factors that govern their differentiation. Here, we identified polarizing conditions to induce an IL22-producing Tc22 subset, which is dependent on IL6 aryl hydrocarbon receptor factor. Further characterization showed this subset was highly cytolytic expressed a distinct cytokine profile transcriptome relative other subsets. In addition, were able control tumor growth well...
Abstract Progressive decline of the adaptive immune system with increasing age coincides a sharp increase in cancer incidence. In this study, we set out to understand whether deficits antitumor immunity advanced promote tumor progression and/or drive resistance immunotherapy. We found that multiple syngeneic cancers grew more rapidly aged versus young adult mice, driven by dysfunctional CD8+ T-cell responses. By systematically mapping cell profiles within tumors, identified loss...
Immunotherapies have had unprecedented success in the treatment of multiple cancer types, albeit with variable response rates. Unraveling complex network immune cells within tumor microenvironment (TME) may provide additional insights to enhance antitumor immunity and improve clinical response. Many studies shown that NK or innate lymphoid (ILC) regulatory capacity. Here, we identified CD103 as a marker was found on CD56+ were associated poor proliferative capacity tumor-infiltrating...
<div>Abstract<p>Immunotherapies have had unprecedented success in the treatment of multiple cancer types, albeit with variable response rates. Unraveling complex network immune cells within tumor microenvironment (TME) may provide additional insights to enhance antitumor immunity and improve clinical response. Many studies shown that NK or innate lymphoid (ILC) regulatory capacity. Here, we identified CD103 as a marker was found on CD56<sup>+</sup> were associated...
<p>Fig. S10. CD103+Lin- ILC1-like cells are associated with altered immune landscape within the TME.</p>
<p>Fig. S5. Identifying cellular clusters from scRNA-seq of ovarian tumours.</p>
<p>Fig S4. CD101 and GITR expression is expressed on CD103+CD49a+CD56+Lin- ILCs but not other NK cell subsets.</p>
<p>Fig. S1. Gating strategy for intratumoural ILCs.</p>
<p>Fig. S7. Intratumoural CD103+CD56+Lin- ILCs displayed unique profile of transcription factors.</p>
<p>Fig. S2. CD103+CD56+Lin- ILCs express distinct gene expression compared to CD103-CD56+Lin-ILCs.</p>
<p>Fig. S9. CD103+CD56+Lin- ILCs express distinct signatures compared to other ILC subsets.</p>